Home>>Signaling Pathways>> Others>> Others>>Ioversol (MP-328)

Ioversol (MP-328) Sale

(Synonyms: 碘佛醇; MP-328) 目录号 : GC30133

Ioversol is an organoiodine compound used as a radiographic contrast agent.

Ioversol (MP-328) Chemical Structure

Cas No.:87771-40-2

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥638.00
现货
10mg
¥580.00
现货
50mg
¥1,250.00
现货
100mg
¥1,696.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment:

Cell viability is assessed by using the MTT uptake assay. The conversion of MTT, a tetrazolium salt, into formazan depends on the activity of a group of mitochondrial dehydrogenases and, thus, is an indicator of cell metabolic activity. The color of MTT tetrazole salt is measured with a spectrophotometer at the wavelength of 570 nm. Briefly, fresh MTT solution (10 mg/mL in 1× PBS) isadded (1:20 volume of medium) after removing the medium and the cells are incubated for 1.5 h. The cells are lysed and purple formazan dissolved into the solution by overnight incubation with MTT lysis buffer. The results are expressed as the percentage of undamaged control cells, assuming the absorbance of control wells as 100%.

References:

[1]. Yang D, et al. Selective inhibition of the reverse mode of Na(+)/Ca(2+) exchanger attenuates contrast-induced cell injury. Am J Nephrol. 2013;37(3):264-73. doi: 10.1159/000348526. Epub 2013 Mar 13.
[2]. Heyman SN, et al. Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol. 1993 Apr;28(4):313-8.

产品描述

Ioversol is an organoiodine compound used as a radiographic contrast agent.

Chemical Properties

Cas No. 87771-40-2 SDF
别名 碘佛醇; MP-328
Canonical SMILES O=C(C1=C(I)C(N(C(CO)=O)CCO)=C(I)C(C(NCC(O)CO)=O)=C1I)NCC(O)CO
分子式 C18H24I3N3O9 分子量 807.11
溶解度 DMSO : ≥ 100 mg/mL (123.90 mM) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.239 mL 6.1949 mL 12.3899 mL
5 mM 0.2478 mL 1.239 mL 2.478 mL
10 mM 0.1239 mL 0.6195 mL 1.239 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Ioversol

Intravenous iodinated contrast media are poorly excreted into breastmilk and poorly absorbed orally so they are not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives an iodine-containing contrast medium.[1-4] However, because there is no published experience with ioversol during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.

[Usefulness of ioversol (MP-328) in angiocardiography--a multicenter comparative study with iopamidol]

A randomized, controlled study was conducted to compare the radiographic efficacy, safety and usefulness of ioversol and iopamidol in 146 patients undergoing angiocardiography at six institutions. The hemodynamic and electrocardiographic effects were clinically insignificant and comparable for both agents. Ioversol demonstrated lower incidence of adverse reactions and less heat sensation in left coronary arteriography than those with iopamidol. Overall radiographic efficacy with ioversol was slightly better than with iopamidol, according to the evaluation by both investigators and committee members. Ioversol appears to be very useful for angiocardiography. This comparative study demonstrated the value of safety and efficacy evaluation criteria suggested by the preceding clinical trial with ioversol.